Akebia Therapeutics financials
$0.8861−0.78%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.1M | $53.5M | $57.6M | $58.8M | $62.5M | $57.3M | $46.5M | $37.4M | $43.6M | $32.6M | $56.2M | $42.0M |
| Gross profit | $38.7M | $41.3M | $45.1M | $49.4M | $52.6M | $49.7M | $26.1M | $23.3M | $26.6M | $21.0M | $10.5M | $33.0M |
| Gross margin | 78.8% | 77.0% | 78.2% | 84.0% | 84.1% | 86.7% | 56.2% | 62.2% | 60.9% | 64.4% | 18.7% | 78.6% |
| Operating income | -$6.3M | -$4.7M | -$8.6M | $4.4M | $14.1M | $13.5M | -$14.3M | -$12.5M | -$8.7M | -$14.9M | $1.9M | -$13.0M |
| Net income | -$8.9M | -$9.1M | -$12.2M | $540.0K | $247.0K | $6.1M | -$22.8M | -$20.0M | -$8.6M | -$18.0M | $614.0K | -$14.5M |
| Net margin | −18.1% | −16.9% | −21.2% | 0.9% | 0.4% | 10.7% | −49.0% | −53.5% | −19.7% | −55.2% | 1.1% | −34.5% |
| Diluted EPS | $-0.03 | $-0.03 | $-0.05 | $0.00 | $0.00 | $0.03 | $-0.10 | $-0.10 | $-0.04 | $-0.09 | $0.00 | $-0.08 |
| EBITDA | -$3.8M | -$4.4M | -$8.2M | $4.8M | $14.4M | $13.8M | -$5.0M | -$3.1M | $685.0K | -$5.5M | $10.8M | -$3.5M |
| Operating cash flow | $3.5M | -$21.2M | $31.1M | $28.1M | $22.3M | -$13.6M | -$4.5M | -$6.7M | -$10.1M | -$19.4M | -$2.3M | -$7.2M |
| Free cash flow | $2.4M | -$21.3M | $31.1M | $28.0M | $22.2M | -$13.6M | -$4.5M | -$6.7M | -$10.1M | -$19.4M | -$2.3M | -$7.2M |
| Diluted shares | 269.6M | 267.0M | 241.6M | 274.4M | 271.1M | 241.6M | 218.8M | 210.3M | 209.7M | 205.0M | 190.0M | 188.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.5M | $162.6M | $184.8M | $166.4M | $137.3M | $113.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $49.6M | $48.9M | $48.3M | $47.6M | $47.1M | $46.5M |
| Total assets | $349.7M | $362.5M | $376.6M | $364.2M | $345.6M | $310.2M |
| Total liabilities | $324.6M | $335.1M | $344.0M | $322.6M | $316.4M | $285.6M |
| Shareholders' equity | $25.0M | $27.4M | $32.6M | $41.6M | $29.2M | $24.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology